<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37078350</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6360</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Current rheumatology reviews</Title><ISOAbbreviation>Curr Rheumatol Rev</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome in a Young Woman: A Case Report.</ArticleTitle><Pagination><StartPage>508</StartPage><EndPage>514</EndPage><MedlinePgn>508-514</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1573397119666230420111517</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with variable clinical presentation, including neuropsychiatric manifestations. It has a different diagnostic approach and several different therapeutic options.</AbstractText><AbstractText Label="CASE REPORT" NlmCategory="METHODS">We describe a case of a young woman who first presented with arthritis, serositis, and pancreatitis, and was treated with mycophenolate mofetil initially. The patient presented with neurological symptoms suggestive of neuropsychiatric manifestations three weeks later, confirmed by Brain Magnetic Resonance Imaging (MRI). The treatment was changed to cyclophosphamide; however, the day after the infusion, she developed status epilepticus and was admitted to the intensive care unit. Repeated brain MRI revealed Posterior Reversible Encephalopathy Syndrome (PRES). Cyclophosphamide was discontinued and rituximab was initiated. The patient's neurological manifestations improved, and she was discharged after 25 days of use.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Immunosuppressive agents, such as cyclophosphamide have been described as a potential risk factor for PRES; however, it is not clear from the available literature whether cyclophosphamide therapy is just a marker of more severe SLE or a true risk factor for PRES.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohammed Bawazir</LastName><ForeName>Yasser</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5060-3884</Identifier><AffiliationInfo><Affiliation>Associate Professor of Medicine, Department of Medicine, King Abdulaziz University, Jeddah, KSA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wasim Anshasi</LastName><ForeName>Neda'a</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Internal Medicine Resident, King Abdulaziz University Hospital, Jeddah, KSA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Rheumatol Rev</MedlineTA><NlmUniqueID>101261938</NlmUniqueID><ISSNLinking>1573-3971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020945" MajorTopicYN="Y">Lupus Vasculitis, Central Nervous System</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054038" MajorTopicYN="Y">Posterior Leukoencephalopathy Syndrome</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">PRESS</Keyword><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">and cyclophosphamide</Keyword><Keyword MajorTopicYN="N">autoimmune disease</Keyword><Keyword MajorTopicYN="N">neuropsychiatric lupus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>5</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37078350</ArticleId><ArticleId IdType="doi">10.2174/1573397119666230420111517</ArticleId><ArticleId IdType="pii">CRR-EPUB-131175</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>